Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives
Glucagon-like peptide-1
0301 basic medicine
0303 health sciences
Biodistribution
Diabetes
Insulin
Therapeutics. Pharmacology
RM1-950
Review
Delivery platforms
Oral peptides
DOI:
10.1016/j.apsb.2024.02.019
Publication Date:
2024-02-28T02:13:07Z
AUTHORS (6)
ABSTRACT
Diabetes, characterized by hyperglycemia, is a major cause of death and disability worldwide. Peptides, such as insulin glucagon-like peptide-1 (GLP-1) analogs, have shown promise treatments for diabetes due to their ability mimic or enhance insulin's actions in the body. Compared subcutaneous injection, oral administration anti-diabetic peptides preferred approach. However, biological barriers significantly reduce efficacy peptide therapeutics. Recent advancements drug delivery systems formulation techniques greatly improved therapeutics treating diabetes. This review will highlight (1) benefits therapeutics; (2) delivery, including pH enzyme degradation, intestinal mucosa barrier, biodistribution barrier; (3) platforms overcome these barriers. Additionally, discuss prospects this field. The information provided serve valuable guide future developments
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (193)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....